Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/031819external-prioritypatent/WO2009094528A1/en
Application filed by High Point Pharmaceuticals LlcfiledCriticalHigh Point Pharmaceuticals Llc
Publication of TN2010000346A1publicationCriticalpatent/TN2010000346A1/en
La présente invention concerne des composés chimiques de formule (I) répondant à la definition figurant dans le present mémoire, , des compositions pharmaceutiques et des procédés d'utilisation dans le traitement d'affections ou de troubles à mediation par le TNF-α ou par la PDE4, comprenant mais à titre non limitatif, la polyarthrite rhumatoïde.The present invention relates to chemical compounds of formula (I) as defined herein, pharmaceutical compositions and methods of use in the treatment of mediated affections or disorders by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.
TNP2010000346A2009-01-232010-07-23
TRICYCLIC COMPOUNDS AS SYNTHESIS MODULATORS OF TNF-β LPHA AND PDE4 INHIBITORS
TN2010000346A1
(en)
Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments